DVA DaVitadata gap · 84% coverage
Health Care · Health Care Services · close $187.31 (2026-10-16) · latest quarter in EDGAR: 2026-06-30
DaVita (DVA) has a ThetaGrade House Rating of 54/100 (grade C), ranking #121 of 150 in Health Care. Its strongest pillars are valuation (90) and cash flow (70); its weakest is balance sheet (32). Data gap: 3 factors without usable data, so 84% of the method weight is covered. TTM revenue growth is 6.4% and operating margin 15.2%.
Data as of .
Data gap
No usable data for: Consensus score (1–5), 90-day net rating shift, 4Q gross-margin change. Data gap: no usable data for this factor, so it is left out and its weight is shared among the factors that do have data (no value is imputed). 84% of the full method weight is backed by data.
Analyst sentiment
weight 7.5% · no data · —| Consensus score (1–5) (0.0%)data gap | derived | — |
| 90-day net rating shift (0.0%)data gap | derived | — |
Growth
weight 30.83% (→33.3%) · 44| Revenue growth YoY (TTM) (13.3%) | 6.4% | 30 |
| EPS growth YoY (TTM) (13.3%) | 19.6% | 56 |
| Revenue acceleration (6.7%) | -0.8% | 50 |
Profitability
weight 18.5% (→20.0%) · 59| Operating margin (20.0%) | 15.2% | 59 |
| 4Q gross-margin change (0.0%)data gap | — | — |
Balance sheet
weight 18.5% (→20.0%) · 32| Net debt / EBITDA (10.7%) | 2.81× | 31 |
| Current ratio (5.3%) | 1.47 | 26 |
| Interest coverage (4.0%) | 3.94× | 42 |
Cash flow
weight 12.33% (→13.3%) · 70| FCF margin (6.7%) | 9.6% | 41 |
| FCF yield (6.7%) | 11.0% | 99 |
Valuation
weight 12.33% (→13.3%) · 90| P/E (inverted) (6.7%) | 15.42× | 91 |
| EV/Sales (inverted) (6.7%) | 1.42× | 89 |
Technicals (EOD)
| RSI(14) | 57.6 |
| EMA 9 / 21 | 182.84 / 181.69 · crossed up 2d ago |
| 200-day SMA | 173.37 |
| Volume vs 20d avg | 0.82× |
| 20-day return | 2.3% |
Exit-rule monitor
- EXITRating break: House Rating below 60
Data source per metric (SEC XBRL tag or derivation): Revenue: Revenues · Operating income: OperatingIncomeLoss · Interest expense: InterestExpenseDebt · D&A: DepreciationDepletionAndAmortization · EPS: EarningsPerShareDiluted · Market cap: SEC shares (dei EntityCommonStockSharesOutstanding (cover page)) × EOD close · P/E: EOD close ÷ SEC TTM EPS (EarningsPerShareDiluted).
Get rating changes like DVA's in the free Daily Brief
The market’s key events and signals, digested before the open.
- ✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
- ✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
- ✓ OPEX, FOMC, CPI and jobs-day reminders
Free. Want more? See Premium (waitlist).
FAQ
- What is DVA's House Rating?
- DVA scores 54 out of 100 (grade C) as of 2026-10-16, ranking #121 of 150 Health Care stocks we cover.
- What do analysts say about DVA?
- We do not have enough analyst-sentiment data to score this stock.
- When does DVA report earnings next?
- We do not have a reliable estimate for DVA's next earnings date (irregular SEC filing history); a rough window is 2026-10-18 to 2026-11-07. Check the company's investor-relations page.
- Is DVA a buy?
- ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.
Sources: SEC EDGAR filings (fetched 2026-10-18), Finnhub recommendation trends, Massive EOD prices. Scores are sector percentiles; a factor without usable data is a data gap: it is left out and the remaining weights are renormalized (nothing is imputed). Educational only. Methodology